Raf/MEK/ERK is typically associated with the proliferation and drug resistance of hematopoietic cells, while the activation of the Raf/MEK/ERK cascade is suppressed in some prostate cancer cell lines that have mutations at PTEN and express high levels of activated Akt [44]. Here, AKT1 is linked to prostate carcinoma.